2025
The Role of the Interventional Radiologist in Stopping Bleeding in Cancer Patients
Fish A, Madoff D. The Role of the Interventional Radiologist in Stopping Bleeding in Cancer Patients. Current Oncology Reports 2025, 27: 483-489. PMID: 40120057, DOI: 10.1007/s11912-025-01663-5.Peer-Reviewed Original ResearchUterine artery embolizationBronchial artery embolizationArtery embolizationBronchial arterial chemoembolizationMalignancy-related bleedingLife-threatening complicationsImproved long-term controlMultidisciplinary approachLong-term controlTumor bleedingArterial chemoembolizationSuperselective embolizationIschemic complicationsEmbolization techniquesInterventional radiologistsControl hemorrhageLung cancerHemostatic solutionsCancer patientsEmbolizationEndovascular interventionStop bleedingImprove outcomesBleedingHemorrhageWorse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation
Makarova E, Fan X, Farooqi I, Bakhl K, Murphy T, Stonesifer E, Faust A. Worse clinical outcomes of TACE when liver function is decompensated in a cohort of patients with cirrhosis and HCC waiting for liver transplantation. Journal Of Liver Transplantation 2025, 17: 100257. DOI: 10.1016/j.liver.2024.100257.Peer-Reviewed Original ResearchTrans arterial chemoembolizationDecompensated liver functionHepatocellular carcinomaLiver functionLiver transplantationClinical outcomesRetrospective cohort study of patientsClinical outcomes of patientsWorsening of liver functionCohort study of patientsCompensated liver functionOutcomes of patientsCohort of patientsRetrospective cohort studyStudy of patientsStatistically significant differenceLocoregional therapyArterial chemoembolizationDecompensated cirrhosisPoor outcomePrimary statistical analysisPatientsCirrhosisTransplantationSignificant difference
2022
Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model
Berz AM, Santana JG, Iseke S, Gross M, Pekurovsky V, Laage Gaupp F, Savic LJ, Borde T, Gottwald LA, Boustani AM, Gebauer B, Lin M, Zhang X, Schlachter T, Madoff DC, Chapiro J. Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model. Journal Of Vascular And Interventional Radiology 2022, 33: 764-774.e4. PMID: 35346859, PMCID: PMC9344951, DOI: 10.1016/j.jvir.2022.03.026.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationCytotoxic T-lymphocyte-associated protein 4Rabbit liver tumor modelConventional TACEImmune checkpoint marker expressionLiver tumor modelVX2 rabbit liver tumor modelArterial chemoembolizationBicarbonate infusionImmune responseDifferentiation 3T-lymphocyte-associated protein 4Conventional transcatheter arterial chemoembolizationTumor modelCell death protein 1Marker expressionIntratumoral T cellsImmune checkpoint markersT cell infiltrationDeath protein 1Antigen-presenting cellsImmune cell recruitmentNew Zealand white rabbitsZealand white rabbitsAPC infiltration
2018
Primary hepatic neuroendocrine carcinoma: report of two cases and literature review
Zhao ZM, Wang J, Ugwuowo UC, Wang L, Townsend JP. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clinical Pathology 2018, 18: 3. PMID: 29507528, PMCID: PMC5831736, DOI: 10.1186/s12907-018-0070-7.Peer-Reviewed Case Reports and Technical NotesTranscatheter arterial chemoembolizationTreatment optionsLiver biopsyNeuroendocrine carcinomaSomatostatin analoguesLiver protectionLiver lobeNon-hepatic originHepatic hilar lymph nodesSmall cell neuroendocrine carcinomaHepatic neuroendocrine carcinomaIneffective treatment optionsSymptoms of jaundiceInitial hospital admissionHilar lymph nodesSurvival of patientsLimited treatment optionsRight liver lobeUnique clinical featuresAvailable treatment optionsHepatic portal veinAbdominal painLiver transplantSurgical resectionArterial chemoembolization
2017
Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects
Savic LJ, Chapiro J, Geschwind JH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. HepatoBiliary Surgery And Nutrition 2017, 6: 7-21. PMID: 28261591, PMCID: PMC5332218, DOI: 10.21037/hbsn.2016.11.02.Peer-Reviewed Original ResearchIntra-arterial therapyConventional transcatheter arterial chemoembolizationLoco-regional therapyIntrahepatic cholangiocarcinomaOnly curative treatment optionUnresectable intrahepatic cholangiocarcinomaCurative treatment optionIntra-arterial administrationTranscatheter arterial chemoembolizationConversion of patientsDrug-eluting beadsTreatment escalationY90-RESystemic chemotherapyDEB-TACEPalliative treatmentProspective trialSurvival benefitArterial chemoembolizationCombination regimensPalliative approachClinical evidenceLate presentationPoor prognosisTherapeutic options
2016
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization
Gorodetski B, Chapiro J, Schernthaner R, Duran R, Lin M, Lee H, Lenis D, Stuart EA, Nonyane BA, Pekurovsky V, Tamrazi A, Gebauer B, Schlachter T, Pawlik TM, Geschwind JF. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization. European Radiology 2016, 27: 526-535. PMID: 27277261, PMCID: PMC5470590, DOI: 10.1007/s00330-016-4445-9.Peer-Reviewed Original ResearchConceptsMedian overall survivalPortal venous thrombosisAdvanced-stage hepatocellular carcinomaConventional TACEDEB-TACEHepatocellular carcinomaOverall survivalAdverse eventsBeads TACEDrug-eluting bead transcatheter arterial chemoembolizationConventional trans-arterial chemoembolizationPropensity scoreDrug-eluting beads TACECommon adverse eventsConclusionOur retrospective studyEqual safety profileChild-Pugh classMethodsThis retrospective analysisPortal vein thrombosisPost-embolization syndromeTranscatheter arterial chemoembolizationStage hepatocellular carcinomaTrans-arterial chemoembolizationSub-group analysisArterial chemoembolizationAutomatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility
Wang Z, Hansis E, Chen R, Duran R, Chapiro J, Sheu YR, Kobeiter H, Grass M, Geschwind JF, Lin M. Automatic bone removal for 3D TACE planning with C-arm CBCT: Evaluation of technical feasibility. Minimally Invasive Therapy & Allied Technologies 2016, 25: 162-170. PMID: 26923140, PMCID: PMC4833567, DOI: 10.3109/13645706.2015.1129970.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationAutomatic bone removalGeneral usabilityBone removalArterial chemoembolizationSoft tissue retentionUnderwent transcatheter arterial chemoembolizationTechnical feasibilitySoft tissueTissue retentionModel-based segmentationBetter removalFour-level scoreInter-reader agreementClinical valueInterventional radiologistsC-arm CBCTAgreement proportionUsabilityCBCT imagingAdequate performanceSpine removalFurther assessmentChemoembolizationC-arm
2015
Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis
Zacharias A, Jayakrishnan T, Rajeev R, Rilling W, Thomas J, George B, Johnston F, Gamblin T, Turaga K. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLOS ONE 2015, 10: e0139940. PMID: 26448327, PMCID: PMC4598149, DOI: 10.1371/journal.pone.0139940.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionTranscatheter arterial chemoembolizationColorectal Liver MetastasesSystemic therapyOverall survivalHepatic arterial infusion groupTranscatheter arterial chemoembolization groupLiver MetastasesConcurrent systemic therapyMedian overall survivalMeta-analysisMedian OSSystemic chemotherapyArterial chemoembolizationTumor responseTreatment toxicityArterial infusionFirst-lineSurvival outcomesRadioembolizationHepatic arteryPrimary outcomeSecondary outcomesTherapyPatientsRadiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement
Chockalingam A, Duran R, Sohn JH, Schernthaner R, Chapiro J, Lee H, Sahu S, Nguyen S, Geschwind JF, Lin M. Radiologic-pathologic analysis of quantitative 3D tumour enhancement on contrast-enhanced MR imaging: a study of ROI placement. European Radiology 2015, 26: 103-113. PMID: 25994198, PMCID: PMC4654989, DOI: 10.1007/s00330-015-3812-2.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationHCC patientsIpsilateral placementTumor enhancementHepatocellular carcinoma patientsROI placementContrast-enhanced MR imagingRadiologic-pathologic analysisArterial chemoembolizationCarcinoma patientsPathological correlationIntra-class correlationPatientsMR imagingClinical methodsMedian differencePathologyInterest placementHistopathology
2014
Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma
Boehm L, Jayakrishnan T, Miura J, Zacharias A, Johnston F, Turaga K, Gamblin T. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. Journal Of Surgical Oncology 2014, 111: 213-220. PMID: 25176325, DOI: 10.1002/jso.23781.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationUnresectable intrahepatic cholangiocarcinomaResponse to therapyDEB-TACEIntrahepatic cholangiocarcinomaOverall survivalHepatic arteryDrug-eluting bead transcatheter arterial chemoembolizationTumor response to therapyGrade III/IV toxicityMedian overall survivalHepatic arterial infusionMedian OSTumor responseArterial chemoembolizationArterial infusionPrimary outcomeSecondary outcomesTherapyMeta-analysisMonthsTumorCholangiocarcinomaPatientsArtery
2012
Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization
Lin M, Pellerin O, Bhagat N, Rao P, Loffroy R, Ardon R, Mory B, Reyes D, Geschwind J. Quantitative and Volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors Measurements: Feasibility of a Semiautomated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization. Journal Of Vascular And Interventional Radiology 2012, 23: 1629-1637. PMID: 23177109, PMCID: PMC3579576, DOI: 10.1016/j.jvir.2012.08.028.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleHumansImaging, Three-DimensionalLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPattern Recognition, AutomatedReproducibility of ResultsSensitivity and SpecificitySoftwareSoftware ValidationTreatment OutcomeTumor BurdenConceptsTranscatheter arterial chemoembolizationArterial chemoembolizationHepatocellular carcinomaDrug-eluting bead transcatheter arterial chemoembolizationSingle-institution prospective studyResponse Evaluation CriteriaContrast-enhanced magnetic resonanceHepatic tumor volumeSolid tumor measurementsThree-dimensional volumetric assessmentMagnetic resonanceIntraarterial therapyProspective studyTumor responseClinical correlationTumor measurementsTumor volumeTumor enhancementInterventional radiologistsPatientsVolumetric assessmentChemoembolizationEuropean AssociationVolume assessmentVoxel basisIntraprocedural C-Arm Dual-Phase Cone-Beam CT: Can It Be Used to Predict Short-term Response to TACE with Drug-eluting Beads in Patients with Hepatocellular Carcinoma?
Loffroy R, Lin M, Yenokyan G, Rao PP, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Liapi E, Geschwind JF. Intraprocedural C-Arm Dual-Phase Cone-Beam CT: Can It Be Used to Predict Short-term Response to TACE with Drug-eluting Beads in Patients with Hepatocellular Carcinoma? Radiology 2012, 266: 636-648. PMID: 23143027, PMCID: PMC3558876, DOI: 10.1148/radiol.12112316.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsArea Under CurveCarcinoma, HepatocellularChemoembolization, TherapeuticCone-Beam Computed TomographyDoxorubicinFemaleHumansLeast-Squares AnalysisLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedPredictive Value of TestsProspective StudiesRadiation DosageROC CurveSwineTreatment OutcomeConceptsDual-phase cone-beam CTTranscatheter arterial chemoembolizationPartial tumor responseDrug-eluting beadsTumor responseTumor enhancementCone-beam CT scansHepatocellular carcinomaLogistic regression modelsCone-beam CTVenous phaseCT scanMR findingsMultivariate logistic regression modelMR imagingHCC tumor responseRadiation doseDoxorubicin-eluting beadsMagnetic resonance imagingInstitutional review boardArterial chemoembolizationLiver (EASL) guidelinesRegression modelsProspective studyHCC lesions
2010
Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma
Ahrar J, Gupta S, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P, Bedikian AY. Response, Survival, and Prognostic Factors After Hepatic Arterial Chemoembolization in Patients With Liver Metastases From Cutaneous Melanoma. Cancer Investigation 2010, 29: 49-55. PMID: 21166498, DOI: 10.3109/07357907.2010.535052.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationOverall survivalCutaneous melanoma metastaticExtrahepatic metastatic sitesHepatic arterial chemoembolizationMedian overall survivalLactate dehydrogenase levelsType of treatmentMelanoma metastaticRadiologic responseDisease stabilizationLiver metastasesMost patientsPatient ageArterial chemoembolizationPrognostic factorsLiver diseaseMetastatic sitesCutaneous melanomaMedical recordsDehydrogenase levelsPatientsSignificant predictorsChemoembolizationSurvivalEvaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT
Lin M, Loffroy R, Noordhoek N, Taguchi K, Radaelli A, Blijd J, Balguid A, Geschwind J. Evaluating tumors in transcatheter arterial chemoembolization (TACE) using dual-phase cone-beam CT. Minimally Invasive Therapy & Allied Technologies 2010, 20: 276-281. PMID: 21082901, PMCID: PMC4337876, DOI: 10.3109/13645706.2010.536243.Peer-Reviewed Original ResearchConceptsTranscatheter arterial chemoembolizationTumor-feeding vesselsParenchymal stainingTACE treatmentArterial chemoembolizationContrast injectionDual-phase cone-beam CTTumor feeding vesselsDrug-eluting beadsContrast-enhanced scansDegree of embolizationFeeding vesselsMR/CTSingle injectionCatheter positionInitial experienceCBCT scansCone-beam CTEmbolization effectConventional CTCTChemoembolizationC-armInjectionCBCT systemHepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver
Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, Wallace MJ, Murthy R, Tam A, Hwu P. Hepatic Artery Chemoembolization in Patients With Ocular Melanoma Metastatic to the Liver. American Journal Of Clinical Oncology 2010, 33: 474-480. PMID: 19935383, DOI: 10.1097/coc.0b013e3181b4b065.Peer-Reviewed Original ResearchConceptsHepatic arterial chemoembolizationOcular melanoma metastaticProgression-free survival durationMedian OS durationOverall survivalLactate dehydrogenase levelsMelanoma metastaticRadiologic responseLiver involvementSurvival durationOS durationDehydrogenase levelsResponse rateBaseline lactate dehydrogenase levelsHigher lactate dehydrogenase levelsMedian overall survivalTumor response rateHepatic artery chemoembolizationShorter overall survivalStable diseaseDisease stabilizationProgressive diseaseArterial chemoembolizationMost patientsPartial response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply